SynthesisRevista peruana de medicina experimental y salud publica2024

Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.

Agustín Ciapponi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.